Efficient and Effective Review of Clinical Trial Safety Data Using Interactive Graphs and Tables

  • Harry SouthworthEmail author


Clinical trials collect a great deal of data relating to the safety of the trial participants. The data are complex in nature and traditional approaches to data review involve using summary tables and listed data. An alternative approach to the review of clinical trial safety data is presented, allowing reviewers to access individual subject data via hyperlinked plots and tables. Examples of presentations of data for very large studies, and of the inclusion outputs from modern statistical methods are demonstrated.


Random Forest Patient Report Graphical Presentation Patient Identifier Scalable Vector Graphic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Amit O, Heiberger RM, Lane PW (2007) Graphical approaches to the analysis of safety data from clinical trials. Pharmaceut Stat 7:20–35CrossRefGoogle Scholar
  2. Berry SM, Berry DA (2004) Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics 60:418–426PubMedCrossRefGoogle Scholar
  3. Breiman L (2001) Random forests. Mach Learn 45:5–32CrossRefGoogle Scholar
  4. Firth D (1993) Bias reduction of maximum likleihood estimates. Biometrika 80:27–38CrossRefGoogle Scholar
  5. Friedman J (2001) Greedy function approximation: a gradient boosting machine. Ann Stat 29:1180–1232CrossRefGoogle Scholar
  6. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefGoogle Scholar
  7. Lin X, Parks D, Zho L, Curtis L, Stell H, Rut A, Mooser V, Cardon L, Menius A, Lee K. Truncated robust distance for clinical laboratory safety data monitoring and assessment. J Biopharm Stat (to appear)Google Scholar
  8. Penny KI, Jolliffe IT (2001) A comparison of multivariate outlier detection methods for clinical laboratory safety data. Statistician 50:295–308CrossRefGoogle Scholar
  9. Ridker P, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Børge BA, Nordestgaard G, Shepherd J, Willerson JT, Glynn RJ (2008) Rosuvastatin to prevent vascular events in men and women with. New Engl J Med 359:2195–2207PubMedCrossRefGoogle Scholar
  10. Southworth H (2008) Detecting outliers in multivariate laboratory data. J Biopharmaceut Stat 18:1178–1183CrossRefGoogle Scholar
  11. Southworth H, O’Connell M (2009) Data mining and statistically guided clinical review of adverse event data in clinical trials. J Biopharm Stat 19:803–817PubMedCrossRefGoogle Scholar
  12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 361:1045–1057PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2012

Authors and Affiliations

  1. 1.AstraZenecaMacclesfieldUK

Personalised recommendations